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The genetic heterogeneity of hepatitis B virus (HBV) genotypes and subgenotypes was investigated by directly sequencing amplified PreS, S
and P genes of HBV isolates obtained from the plasma of 99 subjects with chronic HBV infection. Genotype D showed the greatest intragenotypic
and intrasubgenotypic divergence: in particular, the a determinant was mutated in 58.2% of the genotype D patients, two of whom showed
prototypic vaccine-induced escape mutants at codon 145. Moreover, five sites under significant positive selection were found in the S protein of
the D isolates: one in the a determinant and four in the highly hydrophobic C terminal.
Our results suggest that careful surveillance of vaccine-induced escape mutants should be considered in populations with highly frequent
genotype D infections, and raise questions concerning the possible relationship between the genetic heterogeneity, host immunity and
pathogenicity of this HBV genotype.
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Hepatitis B virus (HBV) is a partially double-stranded DNA
virus of the Hepadnaviridae family that infects an estimated
300 million people worldwide. What makes it a unique DNA
virus is its use of an intermediate RNA and a reverse
transcriptase (rt) step during replication, which is why its
evolutionary rate of between 1.4 and 4.6×10−5 substitutions
per site per year is higher than that of other DNA viruses
(Okamoto et al., 1987; Orito et al., 1989).
Significant variability in HBV was first recognised in the
early 1970s, when the existence of mutually exclusive⁎ Corresponding author. Dipartimento di Scienze Cliniche “L. Sacco”,
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doi:10.1016/j.virol.2007.03.015determinants (d/y and w/r) coupled with a more conserved
domain (a determinant) were serologically defined at surface
antigen level, and a number of viral serotypes were identified
(Kidd-Ljunggren et al., 2002). The availability of a number of
complete sequences of HBV isolates has led to the identification
of eight genotypes (A–H) largely corresponding to the known
serotypes which, more recently, have been further classified into
subgenotypes with different geographic and ethnic distributions
(Norder et al., 2004).
HBV genotypes have also been associated with different
clinical outcomes (Schaefer, 2005), with genotypes D and F being
associated with more severe disease progression and a worse
prognosis than genotype A (Sanchez-Tapias et al., 2002; Thakur et
al., 2002), although partially contrasting results have been reported
by other authors (Chattopadhyay et al., 2006; Kumar et al., 2005).
A further correlate of the high degree of variability of
HBV is the selection of point mutations in different viral
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the immune response solicited by natural infection or
vaccination can induce the emergence of mutants in the S
gene which, particularly those in the most immunogenic a
determinant, are positively selected by their ability to evade
immune defences (Zuckerman and Zuckerman, 2003).
The aim of this study was to investigate the genetic
heterogeneity of S and P genes in the different HBV genotypes
and subgenotypes, and the prevalence of mutations at nucleo-
tide and amino acid level, particularly those in the common
neutralising epitope (the a determinant) of the HBV surface
antigen and viral reverse transcriptase. We also investigated the
role of selection in driving the heterogeneity of the different
HBV genotypes.
Results
Population characteristics
Genotype D was the most represented in our case file (55
cases, 55.5%), followed by genotype A (30 cases, 30.3%).
Genotypes F and G accounted for respectively seven (7.1%) and
four (4.1%) cases, and genotypes B, C and E for one case each
(1.0%). Thirty-nine patients (39.4%) were co-infected with HIV-
1. Among the HIV-1-positive individuals, 15 (38.5%) were
infected by genotype A, 18 (46.1%) by genotype D, four
(10.2%) by genotype G, and one each (2.6%) by genotypes B
and E.
A complete phylogenetic analysis was made on the whole
S region of the 99 isolates, amplified as reported in Table 1.
The S sequences were 678 nucleotides long (226 aa) in all butTable 1
Primers for HBV–DNA env/pol amplification and sequencing
HBV–PCR Primer name NCT a posit
Outer primers for 1st fragment: set number 1 HBV-3 2474–2497
HBV-15 663–646
Inner primers: set number 3 HBV-7 2965–2984
HBV-4 280–257
Inner primers: set number 4 HBV-5 180–203
ERS-IN3 655–637
Outer primers for 2nd fragment: set number 2 HBV-9 202–220
HBV-6 1108–1085
Inner primers: set number 5 ERS-IN2 409–428
HBV-6 1108–1085
R: A/G; Y: C/T; K: G/T; B: G/T/C; M: A/C; W: A/T.
a NCT: nucleotide.
b S: sense primer.
c AS: antisense primer.two of the isolates, which were 651 and 654 nct because of
deletions in positions 69–95 and 318–341 (aa 23–32 and
aa 106–114). The length of the PreS regions varied from 342
(in 93/99, 94%) to 285 nct, because of deletions affecting
PreS1 (nct: 181–230 and 192–224) in two genotype D
isolates, and PreS2 (the deletion of 1–20 residues between nct
1 and nct 72) in one genotype A and five genotype D
isolates.
The phylogenetic analysis of the 99 isolates (Fig. 1)
showed seven well-supported clades corresponding to the
major HBV genotypes (A–G); their topology was confirmed
by both NJ and ML. Two recombinant isolates were
identified: one showing a shift between genotypes A (in
Pre/S) and G (in gene S), and the other between genotypes
D and A. Different clades supported by significant bootstrap
values were identified within genotypes A, F and D. The
genotype A isolates segregated into two significant clades
(Fig. 1): the first included three isolates corresponding to
A1, and the second 27 isolates corresponding to A2
subgenotypes. Likewise, the genotype F isolates formed
two significant groups matching the F1 (3 sequences) and F2
subgenotypes (4 sequences). The genotype D isolates
showed the most complex topology, with only partially
significant clades corresponding to known subgenotypes D1
(5 isolates), D2 (8 isolates), D3 (40 isolates) and D4 (2
isolates) (Fig. 2).
Distance analysis of S and P genes
Comparison of the mean intergenotypic distances showed
that strain F was the most divergent (the mean distancesion Sequence (5′–3′) Cycling conditions
(S b) GGGRAAYTTTACKGGGCTBTAYTC 45 cycles:
(AS c) AAACGGRCTGAGGCCCMC 95 °C, 50 s
57 °C, 50 s
72 °C, 100 s
(S) ARTCCMGATTGGGACYWCAA 40 cycles:
(AS) TAGAAAATTGAGAGAAGTCCACCA 95 °C, 40 s
54 °C, 40 s
72 °C, 70 s
(S) TAGGACCCCTKCTCGTGTTACAGG 40 cycles:
(AS) TGAGGCCCACTCCCATAGG 95 °C, 40 s
58 °C, 40 s
72 °C, 70 s
(S) GGCGGKGTKTTTCTTGTTG 45 cycles:
(AS) AAGTTGGCGARAARRYRAAAGCCT 95 °C, 45 s
55 °C, 45 s
72 °C, 100 s
(S) CATCCTGCTGCTATGCCTCA 40 cycles:
(AS) AAGTTGGCGARAARRYRAAAGCCT 95 °C, 40 s
58 °C, 40 s
72 °C, 70 s
Fig. 1. Unrooted NJ tree of 99 patient isolates with 28 reference sequences (indicated by accession numbers) using all sequences 1182 nucleotides long. The numbers
on the branches denote bootstrap values (percentages) at NJ analysis, and the asterisks the level of statistical significance of the branch length at ML analysis
(*0.05≤p>0.001 and **p≤0.001; see Materials and methods for details). The A and F subgenotypes are surrounded by ellipses.
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to 0.097 [0.013] in S sequences versus the mean distances
from 0.047 [0.009] to 0.061 [0.008] between the other
genotypes).
Table 2 shows the mean distances between isolates of the
same genotype (intragenotypic distance – IG) or subgenotype
(intrasubgenotypic distance – ISG). The mean intragenotypic
divergence of the genotype D isolates was significantly greater
than that of genotypes A and G in all of the studied portions of
the viral genome. In particular, the a determinant was highly
conserved in genotypes A and G (mean distances 0.9 [0.4] and 0
substitution/102 sites), but showed a divergence of 4.1 [0.9] inthe D strains (Table 2, p<0.001 by the Mann–Whitney test).
The distance between the strains of genotype F was always less
than that observed in genotype D, but the difference was
statistically significant only in the case of the a determinant
(p=0.006).
The mean intrasubgenotypic distances of the most repre-
sented D subgenotypes (D1, D2 and D3) were always greater
than those of the A and F subgenotypes (Table 2). In particular,
comparison of the intrasubgenotype divergences of the two
most represented groups showed that D3 (40 isolates) had
higher values than A2 (27 isolates) in all of the analysed regions
(p<0.001 by Mann–Whitney's test).
Fig. 2. Unrooted NJ tree of 55 genotype D isolates using the entire 1182-
nucleotide fragment. The numbers on the branches denote bootstrap values
(percentages) at NJ analysis. The reference sequences can be recognised based
on their accession numbers. Significant clades have been highlighted.
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of genotype D and HIV-1 infection, although the coinfected
subjects had the highest intragenotypic divergence values in the
S (2.7 sub/102 sites vs. 2.2 sub/102 sites) and a determinant
regions (5.1 sub/102 sites vs. 3.2 sub/102 sites).
Table 3 shows the mean synonymous (dS) and non-
synonymous substitution rates (dN) for the S, a determinant,
PreS and P regions, estimated using the Nei–Gojobori model:dS was always higher than dN regardless of the region (mean
dN/dS ratio 0.4 in the S and P genes, and 0.2 in the a
determinant and PreS2). Genotype D always had the highest
dN, which was about three times higher than that of genotype A
strains in the whole S coding region and 29 times higher in the a
determinant. Similar results were obtained when intrasubgen-
otype dS and dN were compared (data not shown).
PreS/S and P proteins
At protein level, the prevalence of isolates carrying at least
one amino acid mutation was 81.8% (81/99 isolates) in the
small surface antigen, 39.4% (39/99) in the a determinant,
56.7% (55/97) in the PreS proteins, and 92.8% (90/97) in the
polymerase.
The frequency of mutated strains in the S protein was
always more than 70% for genotypes D, A and F, and similar
mutant frequency was observed in all of the most represented
subgenotypes (Table 4); only genotype G did not show any
variation in this region. Limiting the analysis to the a
determinant region among the subjects infected with genotype
D, the mean prevalence of those carrying mutated strains was
58.2%, as against 6.7% in those carrying genotype A
(p<0.001 by the χ2 test) and 0% in those carrying genotype
G (p<0.02 by the χ2 test). Likewise, comparing the two
most numerous subgenotypes, the frequency of mutations in
the a determinant was 55% in the D3 strains and 7.4% in the
A2 isolates (p<0.001 by the χ2 test).
Figs. 3A/B shows the amino acid mutations affecting more
than 10% of the isolates, as deduced from the genotype A and D
PreS/S sequences. All of the substitutions and affected amino
acids are described in detail in the Supplementary Tables S1 and
S2. The most frequent surface antigen mutation in the D strains
was the substitution of S at site 207, which affected a mean
34.5% of D isolates and 32.5% of the D3 strains. Four mutations
were highly prevalent among strains infecting HIV1-positive
drug addicts (all D3): an S to T substitution in position 90 of
PreS1 (prevalence among drug addicts 7/9, 77.8%); T31A in
PreS2 (6/9, 66.7%); T125M in S protein (7/9, 77.8%); and
P127T/L/A (8/9, 88.9%), which was also but less frequently
present among the non-IVDUs (8/31, 25.8%). These mutations
were frequently associated with each other: nine isolates (seven
from IVDUs, one from a subject at risk for sexual transmission,
and one without known risk) carried a variant characterised by
three or four of these substitutions. All of these subjects were
HIV-1-positive.
Known escape mutants were found in two patients, both
carrying genotype D (2/55, 3.6%) and subgenotype D3 (2/40,
5%): one isolate was characterised by the G to A substitution
at amino acid residue 145 (G145A), and the other showed
the prototypic G to R substitution at the same position
(G145R).
Of the 32 genotype D isolates mutated in the a determinant,
16 (50%) showed mutations only in the first loop, 1 (3%) only
in the second loop, and 10 (31.2%) in both.
Figs. 3C/D shows the mutations in the polymerase protein
affecting more than 10% of the genotype A and D isolates (see
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concerning the individual substitutions).
The most frequent mutations affecting the viral polymer-
ase included two associated with resistance to lamivudine: at
site rt204 (the typical M to V/I substitution in the YMDD
motif) and rt180 (shift from L to M). At the time of
enrolment, 27 patients had been treated with lamivudine for
HIV-1 infection for more than six months. Sixteen of them
(59.2%) had the rtM204V/I mutation; the proportion of
resistant strains was 81.8% (9/11) among the subjects with
genotype A and 58.3% (7/12) in those with genotype D,
whereas none of the four subjects carrying other genotypes
(two with genotype G and two with genotype F) had mutant
strains in the YMDD motif.
Site-specific selection pressure in S and P proteins
After excluding the isolates showing recombination, dele-
tions or premature stop codons, the analysis was based on a total
of 49 type D, 28 type A, three type G and seven type F isolates.
Model M2 (selection) was significantly better at the
likelihood ratio test than M1 (neutral) only in the case of
genotypes A and D, thus suggesting the presence of positive
selection in these strains but not in the others (Table 5). No
significant selection pressure was detected in the PreS coding
region (dN/dS=0.32 in genotype D, and 0.67 in genotype A).
In the S gene, the genotype D isolates showed five sites under
positive selection at the 95% level of significance (5/226, 2.2% –
Fig. 3A). In particular, one of the selected sites in the genotype D
isolates was localised in the a determinant: the substitution of
the Y in position 134 (present in all the D subgenotypes) by N or
S or F. The other four were in the C-terminal of the S protein
(S204N/R/T, Y206S/C/F/N, S207N/R/H/Tand S210R/H/N). No
sites under significant selective pressure were identified in the S
coding region of A strains (Fig. 3B).
Analysis of the polymerase coding sequences (Figs. 3C/D)
showed four sites under significant positive pressure in the
genotype D isolates. There was one in the spacer (K106R/N)
and three in the rt domain: rtY54D/H/N, rtQ215S/P/E/H (not
included in the Fig. 3C because its frequency among the
isolates was 7.7%, slightly less than 10%), and rtI266R/V (in
the D1, D2 and D4 subgenotypes) or rtV266I/R (in the D3
subgenotype). All of the three sites under positive selection in
the genotype A isolates were included in the RT protein, and
two (rtM204: ω2 =5.5, p=0.99 and rtL180: ω2 =5.3, p=0.97)
were associated with lamivudine resistance. Limiting the
analysis to the patients on lamivudine treatment at enrolment,
significant positive selection was also found in sites rt204 and
180 of the genotype D isolates (ω2 =2.9, p=0.99 and ω2 =2.8,
p=0.96, respectively).
Because of the overlap of the S and P coding regions, six of
the most frequent mutations in genotype D and three in
genotype A affected both proteins (highlighted in the Fig. 3 by
letters). We analysed codon rt215 of the P protein, and codon
207 of the S protein, with particular attention because both were
under significant selection in genotype D. ML analysis showed
ω=5.96±1.27 in codon 207, and ω=3.69±0.49 in codonrt215. Moreover, mutation rt215 was always accompanied by
mutation 207, but only nine of the 19 strains with mutation 207
also had mutation rt215.
Interestingly, two contiguous codons of the RT region
(I53V/S in genotype A and Y54D/H/N in genotype D isolates),
both under selective pressure, overlapped on site 45 of the S
region.
SLAC analysis of the PreS/S sequences showed that the
greatest frequency of sites under purifying selection was in the
PreS1 region (13 of the 59 studied sites, 22.0%) followed by
PreS2 (7/55, 12.7%) and S protein (10/226, 4.4%). In strain A,
only one amino acid was under significant negative pressure in
the S protein (G44). All of the 30 negatively selected sites found
in the P protein of genotype D (30/394, 7.6%), as well as the
eight (8/394, 2%) found in genotype A, were included in the rt
domain.
Discussion
Interest in studying HBV genotypes has increased since it
has been shown that they can affect different infection
outcomes (Kao et al., 2000; Sanchez-Tapias et al., 2002; Shiina
et al., 1991a,1991b; Sumi et al., 2003; Thakur et al., 2002;
Tsubota et al., 2001; Yuen et al., 2003) and treatment responses
(Erhardt et al., 2005; Zollner et al., 2002), but the intrinsic or
extrinsic factors explaining such influences are still unknown.
A number of observations suggest that the different genetic
heterogeneity of viral genotypes could be one of these factors
(Li et al., 1993; McMillan et al., 1996; Rodriguez-Frias et al.,
1995).
Interestingly, we found that the mean intragenotypic distance
of type D strains was significantly higher than that of types A
and G in both PreS/S and P sequences.
The existence of subgenotypes with different ethno/geo-
graphic distributions has recently been demonstrated for
genotypes A, B, C, D and F. In relation to the genotypes
present in our population, three subgenotypes have so far been
identified in genotype A (Kramvis et al., 2002; Makuwa et al.,
2006), two in genotype F (Arauz-Ruiz et al., 1997), and five in
genotype D (Banerjee et al., 2006; Norder et al., 2004). This last
is the most widespread genotype, being highly prevalent in the
Mediterranean area, Middle East, India, Indonesia, Australia
and Papua. It has also been isolated in South Africa, Somalia
and Alaska (Norder et al., 2004). It has been suggested that this
geographic dispersion of genotype D is one of the reasons for its
highly complex phylogenesis, and so we decided to extend the
analysis of genetic variability to the subgenotypes. The mean
distances of the D1, D2 and D3 subgenotypes (the most
represented in our subjects infected with type D) were greater
than those of all the A and F subgenotypes, particularly in the a
determinant region, which suggests that the genetic hetero-
geneity of genotype D does not just depend on its phylogenetic
complexity and is not characteristic of a specific geographic or
ethnic subgroup.
As also suggested by the observation that mean dN values
were always higher in genotype and subgenotypes D, its high
degree of polymorphism at nucleic acid level was accompanied
Table 2
Mean intragenotyipc (IG – bold) and intrasubgenotypic (ISG – italic) genetic distances (substitution/102 sites) and standard errors (SE) of the S, a determinant, PreS
and P regions in the study isolates
Coding
region
Mean intragenotype/intrasubgenotype distances (SE)
ISG IG ISG IG IG ISG IG
D1 D2 D3 D4 D A1 A2 A a G a F1 F2 F
S 2.2 (0.4) 1.6 (0.3) 2.4 (0.3) 0.7 (0.3) 2.5 (0.3) 0.2 (0.1) 0.8 (0.2) 1.0 (0.2) 0 0.2 (0.2) 0.2 (0.1) 1.3 (0.3)
p b – <0.001 0 0.1
a determinant 2.1 (0.8) 2.2 (0.8) 3.4 (0.7) 0.7 (0.7) 4.1 (0.9) 0.5 (0.5) 0.5 (0.5) 0.9 (0.4) 0 0 0 2.4 (1.1)
p b – <0.001 0 0.006
PreS 4.6 (1.0) 2.6 (0.7) 3.2 (0.5) 3.8 (1.3) 4.1 (0.6) 1.2 (0.6) 0.4 (0.1) 1.5 (0.3) 1.0 (0.5) 0.3 (0.3) 0 3.6 (0.9)
p b – <0.001 0.007 0.6
P 3.1 (0.4) 2.1 (0.3) 3.0 (0.3) 1.6 (0.4) 3.1 (0.3) 0.8 (0.2) 0.9 (0.1) 1.3 (0.2) 0.3 (0.2) 0.5 (0.2) 0.1 (0.1) 2.0 (0.3)
p b – <0.001 0.003 0.7
IG: intragenotypic distances; ISG: intrasubgenotypic distances.
a One A and one G isolate were excluded from the PreS and P gene analysis because they were recombinant strains in these regions.
b p: comparison between D and all the other genotypes; Mann–Whitney's non-parametric test.
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variant S protein being found in more than 80% of cases. In
particular, 58% of the patients infected with this genotype
carried a virus mutated in the a determinant, whereas the
prevalence of a determinant variants was about ten times less in
genotype A, and no substitution was found in genotype G.
Likewise, the frequency of a determinant mutants in D3 strains
was 55%, as against 7.4% in A2 and no mutants in F1.
The a determinant, which spans amino acids 124–147 of the
surface antigen, is a conformational epitope characterised by
two hydrophilic loops that has a common structure in all
genotypes (Zuckerman, 2000). It induces neutralising anti-
bodies, and variations in the sequence of the a determinant may
permit immune evasion by significantly changing its antigenic
structure. In particular, mutations in the second loop of the a
determinant have been frequently described in association with
anti-hepatitis B vaccine-induced escape mutants (Zuckerman
and Zuckerman, 2003).
The majority of the mutations observed in our isolates were
located in the first loop of the a determinant, but more than 30%
of patients carried strains mutated in the second loop. In
particular, two subjects carrying subgenotype D3 and neverTable 3
Mean synonymous (dS
a) and non-synonymous (dN
a) (per 102 sites) distances of
the S, a determinant, PreS regions and P by genotype
Region Genotype
D A G F
dS dN dS dN dS dN dS dN
S Mean 4.2 2.0 1.9 0.6 0 0 3.5 0.5
SE 0.8 0.3 0.5 0.1 0 0 1.1 0.3
a determinant Mean 7.5 2.9 3.1 0.1 0 0 8.5 0.5
SE 2.4 0.8 1.2 0.1 0 0 4.0 0.5
PreS Mean 9.7 2.3 1.9 1.0 3.0 0.3 10.9 1.3
SE 1.7 0.5 0.6 0.3 1.8 0.3 3.5 0.6
P Mean 4.3 2.6 1.8 1.1 0 0.4 3.2 1.4
SE 0.9 0.3 0.4 0.2 0 0.2 0.9 0.3
a Estimated using the Nei–Gojobori model. SE: standard error.vaccinated against HBV had strains with a mutation at amino
acid 145, which is the prototype “escape mutant” following
vaccine-induced immunisation (Carman et al., 1990; Seddigh-
Tonekaboni et al., 2001). This finding suggests that escape
mutants may be directly acquired as infecting strains or
spontaneously arise in hosts under selection forces other than
a vaccine-induced immune response; in any case, this finding
seems to be epidemiologically relevant and should be con-
sidered when designing prevention campaigns.
Eighteen subjects carrying HBV genotype D were also
coinfected with HIV-1: there was a particularly high poly-
morphism of the S and a determinant in the isolates obtained
from these individuals, although the greater heterogeneity of the
D strain was not associated with HIV-1 positivity. D genotype is
highly prevalent among Italian IVDUs (Zehender et al., 2003).
For this reason one-half of our HIV-positive individuals with the
D genotype were IVDUs, and the great majority of them (about
80%), plus two other non-IVDUs, were infected by viral strains
characterised by 3–4 mutations in the PreS and a determinant
region. One of these mutations, T125M, has previously been
described by other authors as being associated with IVDUs
(Norder et al., 2004). This explains the high degree of
polymorphism observed in HBV-D infecting the HIV-1-positive
individuals, and suggests the circulation of a specific clade in a
particular group of individuals at high risk of infection, possibly
representing what remains of the hepatitis B epidemic observed
in IVDUs during the late 1970s and 1980s.
One of the possible driving forces of genetic variability is
positive selection, which is usually measured by calculating
the non-synonymous/synonymous substitution rate ratio over
the whole gene sequence. However, as selection generally
acts on only one or a few protein sites, maximum likelihood-
based methods have recently been developed to evaluate
selective pressure at individual sites. ML analysis revealed
positively selected sites in our genotype D and (but only in
the P coding region) genotype A isolates whereas, albeit on a
relatively small number of analysed sequences, the F and G
isolates did not show any codons under significant positive
selection.
Table 4
Frequency of patients carrying mutated strains according to the different HBV genotypes and subgenotypes
Protein % Variant frequency a (mutants/total isolates)
D A G F
D1 (5) D2 (8) D3 (40) D4 (2) Total (55) A1 (3) A2 (27) Total (30) b (4) b F1 (3) F2 (4) Total (7)
S 60 (3) 62.5 (5) 97.5 (39) 100 (2) 89 (49) 100 (3) 77.8 (21) 80 (24) 0 (0) 33.3 (1) 100 (4) 71.5 (5)
p c – 0.2 <0.001 0.2
a determinant 40 (2) 100 (8) 55 (22) 0 (0) 58.2 (32) 0 (0) 7.4 (2) 6.7 (2) 0 (0) 0 (0) 100 (4) 57.2 (4)
p c – <0.001 0.02 0.9
PreS 100 (5) 37.5 (3) 75 (30) 100 (2) 72.7 (40) 100 (3) 34.6 (9) 41.4 (12) 33.3 (1) 0 (0) 0 (0) 0 (0)
p c – 0.005 0.1 <0.001
P 100 (5) 100 (8) 97.5 (39) 100 (2) 98.2 (54) 100 (3) 84.6 (22) 86.2 (25) 33.3 (1) 100 (3) 100 (4) 100 (7)
p c – 0.04 <0.001 0.7
a Frequency of patients carrying mutant strains.
b One A and one G isolate were excluded from the PreS and P gene analysis because they were recombinant strains in these regions.
c p: comparison between genotype D and all the others – χ2 test.
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coding region. Interestingly, only one site (at codon 134) under
selection was found in the a determinant, which frequently
showed the substitution of a residue of tyrosine by serine or
phenylalanine or (in one case) asparagine all of the other four
sites were concentrated in the highly hydrophobic C-terminal of
the small S protein, a transmembrane domain of the HBV
envelope proteins (Bruss, 2004).
At least in genotype D, mutations in the a determinant and
C-terminal of the S protein may play a role in escaping cross-
immunity, which is one of the main determinants of virus
phylogeny (Grenfell et al., 2004). The way in which cross-
immunity affected the selection of the mutants at the above
sites has yet to be clarified. It has been suggested that the
mutation at codon 134 of the a determinant described by other
authors may be an escape mutant (Ogura et al., 1999; Seddigh-
Tonekaboni et al., 2000), and it can be postulated that the
mutation in this site (observed in about 13% of our patients
carrying genotype D) is driven by the degree of humoral
immunity in the population.
The other sites under selection detected in this study were
located in a transmembrane domain of the S protein, a region
that includes potential T-cell epitopes as suggested for codon
207 (Rehermann et al., 1995), which we found to be under
significant positive selection. Mutations at different CTL
epitopes have been previously described, but their role in
evading CTL responses is still unclear (Rehermann and
Nascimbeni, 2005). It can be hypothesised that, in chronically
HBV-infected patients, selection pressure at population level in
the C-terminal portion of the S protein is attributable to the role
that such mutated strains might play in maintaining persistent
infection: in particular, the site 207 mutation was found in more
than one-third of the genotype D isolates.
Analysis of the P protein revealed several sites under
selective pressure, particularly in the rt domain. Two of the three
genotype A sites under selective pressure (rt204 and rt180) were
associated with lamivudine resistance and, as expected, when
the analysis was limited to our lamivudine-treated patients
significant selective pressure on these sites was also detected in
genotype D polymerase. The frequency of resistant strainsseems to be particularly high among patients infected by
genotype A (>80%), according with previous studies which
suggested that there is a more rapid onset of mutations in its
YMDD motif (Buti et al., 2002). It must be born in mind that all
of the lamivudine-treated patients in our study population were
HIV-1-positive subjects chronically treated with the RT
inhibitor at the doses required for antiretroviral therapy, whereas
none of the HIV-1-negative subjects was being treated with
lamivudine at the time of enrolment.
The relatively small number of sites under selection in the P
and S genes may be due to their overlapping, which means that
the mutations in both are subject to multiple driving forces
(constrained evolution; Mizokami et al., 1997). We found that
one site was under significant positive selection at the level of
both S (sites 206/207) and P proteins (site rt215), and our
analysis suggested that the selective pressure in rt215 is less
significant than that in 206 and 207, and is probably a
consequence of it. These results emphasise the need for caution
when interpreting data obtained in a system in which a mutation
in one ORF has consequences in the overlapping ORF (Torresi,
2002). In particular, we found two contiguous sites in the P gene
under significant selective pressure in genotypes A (codon rt53)
and D (codon rt54), both overlapping codon 45 of the surface
antigen, which was highly variable in our case file.
We also attempted to estimate the number and distribution of
negatively selected sites, and found that the highest proportion
under purifying selection in surface antigen was in the PreS1
and PreS2 proteins, possibly because of their important
functional role in cell attachment (Cooper et al., 2003).
Nevertheless, deletions in this region (particularly in the
PreS2 peptide) were highly prevalent in our patients (6.1%,
mainly in genotype D), and it is worth noting that deleted strains
have been associated with progression to more severe hepatitis
B and the development of liver cancer (Huy et al., 2003;
Sugauchi et al., 2003).
There were also two recombinant strains in this region (one
A/G and one D/A switch), which confirms other previously
reported findings (Bollyky et al., 1996; Kato et al., 2002a;
Simmonds and Midgley, 2005) and offers some suggestions for
further studies of the evolutionary mechanisms of HBV.
Fig. 3. Frequency of amino acidmutations in PreS/S protein of (A) genotypeD and (B) genotypeA and in P protein of (C) genotypeD and (D) genotypeA isolates. Only
mutations present in≥10%of the isolates of the same genotype have been represented. X-axis: amino acid sites. Letters indicate S/P overlapping sites. Asterisks indicate
sites under selective pressure.
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Table 5
Likelihood values, the proportion of sites under selective pressure, and ω values
of the S and P coding regions, by viral genotype
Protein Genotype a ω b LnL c of M2 model (p) ω2
b
S D 0.74 2846.10 (<0.001) 6.0
A 0.58 1300.60 (0.05) 5.8
F 0.35 1053.57 (NSd) –
P D 0.55 5714.04 (<0.001) 3.5
A 0.64 2449.25 (<0.001) 5.5
F 0.46 2107.84 (NS) –
a Genotype G was not included because it did not have significant amino acid
variations.
b ω=mean dN/dS for the entire protein; ω2=mean dN/dS for the sites under
selection as estimated by ML.
c Natural logarithm of the likelihood.
d NS: not significant.
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heterogeneous than the other genotypes/subgenotypes. At least
part of this heterogeneity seems to be due to selection at
population level, but it is likely to be driven by mechanisms
other than selection, including greater replication activity,
longer evolution and, possibly, wider dispersion in the general
population.
Our finding that more patients carry D strains with mutations
in the a determinant of antigen S, and the isolation of vaccine-
induced prototypic “escape” mutants in non-vaccinated sub-
jects, indicate the need for careful surveillance of these variants
in areas in which genotype D predominates.
Finally, a number of studies have suggested that the outcome
of the hepatitis due to genotype D is more severe than that due to
genotype A (Sanchez-Tapias et al., 2002; Thakur et al., 2002;
Wai et al., 2005), and that genotype D is less responsive to
alpha-interferon (Erhardt et al., 2005). Further studies are
needed to clarify the possible relationship between the
heterogeneity and greater virulence of this genotype.
Materials and methods
Patient characteristics
The study involved 99 hepatitis B surface antigen (HBsAg)-
positive patients (73 males and 26 females) with chronic HBV
infection and detectable serum HBV–DNA, who were living in
Northern Italy and were observed in the participating hospital
units between 1993 and 2005. All of the patients had had high
serum alanine aminotransferase (ALT) levels for more than
6 months at the time of enrolment. Six patients were born
outside Italy: three in Asia (China, Japan and Indonesia), and
one each in Brazil, Nigeria and Great Britain.
HBV–DNA extraction and amplification by nested PCR
Viral DNA was extracted from the patients' sera (stored at
−30 °C) using the High Pure PCR Template Preparation Kit
(Roche Diagnostics GmbH, Mannheim, Germany) as recom-
mended by the manufacturer. The DNAwas eluted in 50 μL of
nuclease-free distilled water. About 10 μL of the extracted DNAwere amplified in a 50 μL mixture of 1× PCR buffer (10 mmol/
L Tris–HCl, pH 8.3, 50 mmol/L KCl), 1.5 mmol/L MgCl2,
0.2 mmol/L dNTPs, 0.5 μmol/L of the outer primers, and 1 U of
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster
City, CA). Second-round PCR was performed using 5 μL of the
first round PCR product in 50 μL of the same mixture
containing 0.5 μmol/L of the inner primers.
All of the amplification procedures were performed in an
automated thermal-cycler (Applied Biosystems) under similar
conditions: a long initial DNA denaturation step at 95 °C for
9 min, followed by specific cycling conditions, a prolonged
extension step at 72 °C for 10 min, and finally by holding at 4 °C.
Optimal positive and negative controls were included in each
extraction and amplification run.
About 10 μL of the nested PCR products mixed with Blue/
Orange loading dye 6× (Promega, Madison, WI USA) were run
on a ethidium bromide-stained 1.5% agarose gel together with
0.5 μg Φ×174 DNA/Hae III marker (Promega). The expected
bands were detected by means of a UV transilluminator.
Primers
A sequence of about 1365 nucleotides (nct, from nct 2474
to nct 1108 of full-length HBV genome) was obtained by
means of nested PCR amplification using five sets of
degenerated primers to obtain two large outer fragments and
three inner and partially overlapping sequences. The primer
names, sequences and PCR conditions are shown in Table 1.
The nucleotide numeration refers to isolate NDR260 (Okamoto
et al., 1988).
HBV–DNA sequencing
The HBVamplicons were separated from the residual dNTPs
and primers using a commercial purification kit (QIAquick PCR
Purification Kit, Qiagen GmbH, Hilden, Germany). Subse-
quently, the nucleotide sequences of the three amplified
products were determined in both directions by means of the
dideoxy terminator method in the presence of the specific sense
or anti-sense inner primer, using the BigDye Terminator Cycle
Sequencing Ready Reaction Kit and the automated DNA
Sequencer 3100 Genetic Analyzer (Applied Biosystems). In
brief, an optimal quantity of purified PCR product was mixed
with 3.2 pmol of the sequencing primer and 8 μL of the ready
reaction mix in a final volume of 20 μL. Cycle sequencing
reactions were performed for 25 cycles, each of 20 s at 95 °C,
20 s at 55 °C, and 3 min at 60 °C. Excess dye terminators were
removed from the sequencing mixture by means of ethanol/
sodium acetate precipitation. Heat-dried samples were dissolved
in 10 μL of nuclease-free distilled water and loaded onto the
DNA sequencer according to the manufacturer's instructions.
Phylogenetic and statistical analyses
Phylogenetics
The phylogenetic analysis was made on a sequence of
1182 nucleotides encompassing the ORFs coding for the
entire S (including a determinant: amino acids 110–160)
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C-terminal of PreS1, as well as the overlapping ORF coding
for a fragment of 394 amino acids of viral polymerase,
including 106 residues of C-terminal spacer and amino acids
1 to 288 of rt.
The 99 patient isolates were aligned with reference strains
retrieved from the GenBank database and representing all major
HBV genotypes and subgenotypes (see below) using the
CLUSTALW program (Thompson et al., 1994) integrated
within a biological sequence alignment editor (Bio-Edit by Tom
Hall, 2001).
The analyses were made using Phylip vs. 3.5 (Felsenstein,
1989) and PAUP* v. 4.0b10 (by Swofford D., 2001, Sinauer
Ass. Inc. Publ.) software packages.
Best-fitting substitution models and parameters were
estimated using a hierarchical likelihood ratio test implemen-
ted in the Modeltest 3.07 computer program (Posada and
Crandall, 1998), selecting the transversion model (TVM) that
considers different transversion and equal transition rates,
plus invariable sites (proportion=0.49) and γ-distributed rates
among sites (α-shape parameter=0.71). Distances were ex-
pressed in terms of the number of substitutions per site (or 102
sites when indicated). The phenetic analysis was made by
grouping the genetic distances by isolate genotype or sub-
genotype (intragenotypic – IG or intrasubgenotypic – ISG
mean distances).
The phylogeny was reconstructed using the neighbor-joining
(NJ) and maximum-likelihood (ML) methods, and the topolo-
gies confirmed by the two methods were considered significant.
The significances of the interior branches in the NJ were tested
by means of bootstrap analysis with 1000 replicates; bootstrap
values of ≥70% were considered significant. The significance
of the branch length in ML analysis was estimated using the
likelihood ratio test for a branch length of zero, implemented in
PAUP* (where 0.01<p<0.05 is significant, and p<0.01 is
highly significant).
The deduced amino acid sequences were aligned with
reference strains by subgenotype, and the majority-rule
consensus sequence was calculated. Each isolate that differed
from the consensus sequence was defined a mutant.
The inconsistencies in numbering the amino acid sites are
due to the genome-length polymorphism of HBV genotypes. In
order to avoid ambiguities, we restarted numbering PreS/S
proteins at the first codon position of each domain. We used the
new nomenclature proposed by Stuyver for P protein (Stuyver
et al., 2001).
Synonymous (dS) and nonsynonymous (dN) distances were
estimated using the model of Nei and Gojobori (1986) with the
Jukes–Cantor correction and MEGA version 3.1 (Kumar et al.,
2004).
Site-specific selection was evaluated using the following
models implemented in the CODEML program included in the
PAML v.3.14 package (Yang, 1997), which allow for hetero-
geneous ω=dN/dS ratios among codons: M0 (one-ratio),
assuming one dN/dS ratio for all sites; M1 (nearly-neutral),
assuming a proportion of conserved and a proportion of neutral
sites (0<ω<1 or ω=1); and M2 (selection), adding an extraclass of sites under positive selection (ω>1) and representing a
slight modification of the previously described M1 and M2
models (Nielsen and Yang, 1998). The performances of the
models were compared using the likelihood-ratio test, which
allows a comparison of the likelihood of nested models. An
F3×4 codon frequency model was assumed, and k was
estimated by the program. A new empirical Bayes approach
(Bayes Empirical Bayes – BEB) was used to identify specific
sites under positive selection, with a posterior probability of
≥95% (Yang et al., 2005). Isolates showing genotypic
recombinations, nucleotide deletions or premature stop codons
were excluded from the analysis.
Negative selection was evaluated by means of single-
likelihood ancestor counting (SLAC) analysis, which is based
on the method originally described by Suzuki (Suzuki and
Gojobori, 1999) and implemented in the HYPHY software
package (Kosakovsky Pond and Frost, 2005; Pond et al.,
2005).
Strains used for the phylogenetic analysis. The isolates were
aligned with 74 reference strains representative of the major
HBV genotypes (A–G) and the subgenotypes most frequently
found in our study population (A1–3; D1–5; F1,2), whose
accession numbers are: X70185 (Preisler-Adams et al., 1993b);
X51970; M54923; X02763, D00329, AB033558, AB033559
(Okamoto et al., 1988); X01587 (Fujiyama et al., 1983);
X02496 (Bichko et al., 1985); X65257; X65259; AY230128;
X75657, X75658 (Norder et al., 1994); AB036907, AB036910,
AB036912, AB036919, AB036920 (Nakano et al., 2001);
AF160501 (Stuyver et al., 2000); AF405706; AB064310,
AB064311, AB064312, AB064313 (Kato et al., 2002b);
AB056513, AB056515 (Kato et al., 2001); AB048701,
AB048703 (Sugauchi et al., 2001); X80925; Z35716;
AB194950, AB194949, AB194951, AB194952(Kurbanov et
al., 2005);AY090453, AY090458, AY090456, AY090459,
AY090255 (Arauz-Ruiz et al., 2002); V00866 (Ono et al.,
1983); Y07587 (Stoll-Becker et al., 1997); AB078032,
AB078033 (Chen et al., 2003); AF143298 (Preikschat et al.,
1999); M32138 (Tong et al., 1990); V01460 (Galibert et al.,
1979); AF151735 (Gerner et al., 1999); S50225 (Wands et al.,
1992); X69798 (Naumann et al., 1993); AB090270,
AB090269, AB090268 (Duong et al., 2004); AF297621
(Owiredu et al., 2001); U87742 (Bowyer et al., 1997); X72702
(Preisler-Adams et al., 1993a); AB064314; AB086397;
AF223963; AF223962; AF223965; AF280817; AF418674;
AF418682; AJ309371; AY161150; AY161161; AY161157;
AY161140; X85254; X68292; Z72478; M57663; AJ344116.
Sequence accession numbers: the sequences were submitted
to GenBank with assigned accession numbers from EF514251
to EF514349 and EF522104.
Statistical analysis
Mean genetic distances were compared using Mann–
Whitney's non-parametric test for independent samples. p
values of≤0.05 were considered significant. All of the analyses
were performed using the SPSS package v. 13 (SPSS Inc.,
Chicago, IL, USA) or epi-info v.6 (CDC, Atlanta).
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